Law360, New York (July 11, 2006, 12:00 AM EDT) -- Famed trial attorney Mark Lanier doesn’t bestow compliments on pharmaceutical defense firms all that often. Lanier, who yielded first $253 million, and later $13 million, from Merck in the Vioxx trials, could only come up with one firm to compliment when asked about his competition: Dechert.
“In all candor, I have not been too impressed with many others,” Lanier said, singling out Philadelphia-based Dechert partner Hope Freiwald as “top notch.”
Freiwald and partner Diane Sullivan also scored a major win in a Vioxx case, securing a...
Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.